CLINICAL TRIALS PROFILE FOR BYDUREON

505(b)(2) Clinical Trials for BYDUREON

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT04520490 ↗	Brain Activation and Satiety in Children 2	Recruiting	University of Washington	Phase 3	2021-01-28	Childhood obesity and related long-term effects are serious public health problems, but not all children with obesity do well in treatment. This study will test a new combination of family-based behavioral treatment (FBT) with a drug intervention using a glucagon-like peptide-1 receptor agonist (GLP-1RA) exenatide once weekly extended-release (ExQW, Bydureon®) in order to improve obesity intervention outcomes in 10-12-year-old children.
New Combination	NCT04520490 ↗	Brain Activation and Satiety in Children 2	Recruiting	Seattle Children's Hospital	Phase 3	2021-01-28	Childhood obesity and related long-term effects are serious public health problems, but not all children with obesity do well in treatment. This study will test a new combination of family-based behavioral treatment (FBT) with a drug intervention using a glucagon-like peptide-1 receptor agonist (GLP-1RA) exenatide once weekly extended-release (ExQW, Bydureon®) in order to improve obesity intervention outcomes in 10-12-year-old children.

All Clinical Trials for BYDUREON

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00103935 ↗	Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes	Completed	Eli Lilly and Company	Phase 2	2005-02-01	Exenatide LAR is a long-acting release formulation of exenatide, which is a twice-daily dosage form currently under investigation as a potential treatment for people with type 2 diabetes mellitus. This study will assess the safety, tolerability, and pharmacokinetics of Exenatide LAR administered weekly by subcutaneous injection in people with type 2 diabetes mellitus.
NCT00103935 ↗	Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes	Completed	AstraZeneca	Phase 2	2005-02-01	Exenatide LAR is a long-acting release formulation of exenatide, which is a twice-daily dosage form currently under investigation as a potential treatment for people with type 2 diabetes mellitus. This study will assess the safety, tolerability, and pharmacokinetics of Exenatide LAR administered weekly by subcutaneous injection in people with type 2 diabetes mellitus.
NCT00308139 ↗	Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)	Completed	AstraZeneca	Phase 3	2006-04-01	A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release (LAR) on Glucose Control (HbA1c) and Safety in Subjects with Type 2 Diabetes Mellitus Managed with Diet Modification and Exercise and/or Oral Antidiabetic Medications.
NCT00877890 ↗	A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)	Completed	Eli Lilly and Company	Phase 3	2009-03-01	This study will compare the effects of commercially manufactured exenatide once weekly and exenatide BID in subjects whose type 2 diabetes is managed with diet and exercise alone or with oral antidiabetic medications. The study will examine glycemic control (as measured by HbA1C), safety, and tolerability.
NCT00877890 ↗	A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)	Completed	AstraZeneca	Phase 3	2009-03-01	This study will compare the effects of commercially manufactured exenatide once weekly and exenatide BID in subjects whose type 2 diabetes is managed with diet and exercise alone or with oral antidiabetic medications. The study will examine glycemic control (as measured by HbA1C), safety, and tolerability.
NCT01089569 ↗	Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine	Completed	International Diabetes Center at Park Nicollet	N/A	2010-04-01	The primary purpose of this study is to compare the effect on 24-hour blood glucose patterns, HbA1c, and weight management when adding insulin glargine, or exenatide, or a combination of insulin glargine and exenatide to metformin.

Clinical Trial Conditions for BYDUREON

Condition Name

Condition Name for BYDUREON
Intervention	Trials
Type 2 Diabetes	8
Type 2 Diabetes Mellitus	6
Obesity	4
Diabetes Mellitus, Type 2	4

Condition MeSH

Condition MeSH for BYDUREON
Intervention	Trials
Diabetes Mellitus, Type 2	18
Diabetes Mellitus	14
Obesity	5
Parkinson Disease	2

Clinical Trial Locations for BYDUREON

Trials by Country

Trials by Country for BYDUREON
Location	Trials
United States	137
Kuwait	2
Denmark	2
Sweden	2
Italy	2

Trials by US State

Trials by US State for BYDUREON
Location	Trials
Texas	13
Florida	8
California	8
New York	7
Washington	7

Clinical Trial Progress for BYDUREON

Clinical Trial Phase

Clinical Trial Phase for BYDUREON
Clinical Trial Phase	Trials
PHASE1	1
Phase 4	13
Phase 3	10

Clinical Trial Status

Clinical Trial Status for BYDUREON
Clinical Trial Phase	Trials
Completed	23
Recruiting	7
Unknown status	4

Clinical Trial Sponsors for BYDUREON

Sponsor Name

Sponsor Name for BYDUREON
Sponsor	Trials
AstraZeneca	9
The University of Texas Health Science Center, Houston	4
Seattle Children's Hospital	2

Sponsor Type

Sponsor Type for BYDUREON
Sponsor	Trials
Other	41
Industry	15
NIH	2

BYDUREON Market Analysis and Financial Projection

Last updated: April 28, 2026

Bydureon (exenatide extended-release): Clinical-trials update and market analysis with projections

What is Bydureon and where does it sit in the GLP-1 market?

Bydureon is exenatide extended-release (ER), a once-weekly GLP-1 receptor agonist. It targets type 2 diabetes and competes in a crowded class defined by semaglutide and tirzepatide (and, to a lesser extent, other GLP-1s).

Commercial context (2025 market structure):

• The GLP-1 category has shifted from “GLP-1 first generation” to high-dose, oral, and dual-agonist regimens, with tirzepatide (GIP/GLP-1) and semaglutide absorbing a large share of new prescriptions.
• GLP-1 adoption is increasingly driven by therapeutic escalation algorithms and payer coverage rules, not by molecule-level differentiation alone.

Implication for Bydureon:

• Bydureon’s value proposition depends on existing patient penetration, payer-specific formulary placement, and availability/continuity of supply rather than new clinical expansion.

What do clinical-trials updates for Bydureon show in recent years?

Publicly available clinical-trial activity for Bydureon in recent years is limited compared with newer GLP-1 and dual-agonist programs. The operational pattern for legacy GLP-1 ER assets typically includes:

• Post-marketing studies and real-world evidence rather than large Phase 3 outcomes trials.
• Comparative or extension studies focused on glycemic endpoints and tolerability.
• Safety monitoring required by regulators and label maintenance obligations.

Clinical development posture (market reality):

• The competitive landscape has moved toward cardiovascular outcomes, kidney outcomes, and obesity indications for newer agents.
• Bydureon has not broadly driven category-shaping outcomes trials at the same scale as semaglutide/tirzepatide programs.

How does the payer and formulary environment affect Bydureon prospects?

GLP-1 formulary dynamics tend to favor fewer, preferred agents when budgets tighten. For legacy GLP-1s, formulary placement often depends on one or more of:

• Step therapy rules (fail another preferred agent first)
• Prior authorization criteria that align with outcomes evidence
• Net price and rebate structure negotiated to win preferred status

Practical consequence for Bydureon:

• Even with adequate efficacy, Bydureon’s addressable market is typically constrained by coverage preferences for newer GLP-1s and tirzepatide.

What is the likely demand base for Bydureon (diagnosis-to-therapy pipeline)?

The demand base for Bydureon is determined by:

1. Prevalent treated type 2 diabetes patients on injectable therapies
2. Switch behavior driven by tolerability, weight outcomes, and outcomes data
3. Therapy discontinuation for GI adverse events, injection burden, or formulary changes

Relative positioning vs class leaders:

• Semaglutide and tirzepatide have stronger momentum due to broader outcomes narratives and, for many payers, more favorable coverage under fixed cost-effectiveness frameworks.
• Bydureon competes with a smaller “covered legacy injectables” pool.

Market analysis: where Bydureon fits in US and major markets

Key market forces:

• Obesity indication expansion has increased GLP-1 adoption in many markets, but also concentrates brand preference on the agents with the strongest obesity access pathways.
• Patent and lifecycle management influence pricing latitude and promotional spend.
• Manufacturing and device continuity matter for injectable ER products, since injection device friction impacts persistence.

Commercial positioning that typically holds for legacy GLP-1 ER products:

• Retain a share among patients stable on therapy
• Compete on cost when payers restrict newer agents
• Avoid aggressive growth investments unless a specific label expansion or access breakthrough occurs

Revenue and share projection: baseline case and downside/upside bands

Because Bydureon’s recent growth drivers are weaker than newer GLP-1s, projections should be framed as share-stabilization vs continued share erosion depending on payer placement and competitive behavior.

Projection framework (how the market likely moves):

• Base case: modest net decline driven by ongoing switching to preferred newer injectables, offset by inertia for stable patients and any cost-based access wins.
• Downside case: accelerated share loss if payers consolidate to 1 to 2 preferred agents for coverage and step therapy tightens.
• Upside case: stabilization if Bydureon secures or retains favorable formulary status in a subset of plans, or if competitive dynamics weaken due to supply constraints for leaders.

Market projection (directional):

• US growth: unlikely; expected to be flat to declining.
• Global growth: modest or declining depending on local competitive structures, with higher risk in markets where newer GLP-1s are rapidly preferred.

Comparable benchmarks: how legacy GLP-1 ER products typically perform

Across the class, once newer agents establish preferred status:

• Switching rate increases after formulary policy changes
• Persistence becomes the main revenue driver
• Net price pressure rises as incremental buyers shift to preferred agents

For Bydureon specifically, the competitive “ceiling” is likely set by:

• the number of payers that still list it as preferred or as an accessible second option
• the degree to which payers require failure of semaglutide/tirzepatide before authorizing Bydureon

What could change the trajectory for Bydureon?

The most plausible trajectory changers are not new Phase 3 efficacy outcomes but:

• Formulary wins via payer negotiations or health plan contracts
• Supply continuity that avoids stock-outs for injectable ER formulations
• Local label-driven access for diabetes subpopulations where coverage criteria differ
• Generic or biosimilar substitution dynamics for competing GLP-1s, which can temporarily open space for remaining branded options (molecule- and time-specific)

Key risks

1. Competitive preference consolidation: fewer preferred GLP-1s reduce addressable volume for legacy ER products.
2. Switching to higher-efficacy agents: patient and prescriber migration to semaglutide/tirzepatide remains persistent across many formularies.
3. Net price compression: even without category volume loss, legacy brands typically face rebate pressure.

Key opportunities

1. Stability-driven retention: Bydureon can maintain revenue where prescriber inertia and patient stability matter.
2. Cost positioning: targeted access where preferred newer agents are restricted or higher-priced.
3. Localized formulary coverage: plans that prefer injectables with specific budget impact profiles can support continued use.

---

Clinical-to-market execution view

What is the commercial “to-do” logic for Bydureon going forward?

1. Defend persistence: prioritize continuity of therapy and patient support to reduce discontinuation.
2. Win access selectively: target payer contracts where step therapy is less strict and prior authorization criteria are favorable.
3. Maintain manufacturing reliability: device-based injectable ER products are sensitive to distribution disruptions.

Where R&D and trial strategy typically land for legacy GLP-1 ER assets

Legacy assets rarely fund large outcomes trials unless there is a clear payer-driven value hypothesis or a label expansion. Trial activity typically focuses on:

• Real-world safety monitoring
• Label maintenance and subgroup evidence
• Comparative effectiveness within available payer pathways

---

Key Takeaways

• Bydureon (exenatide ER) sits in a GLP-1 market dominated by semaglutide and tirzepatide with aggressive formulary preference dynamics.
• Clinical-trials momentum for Bydureon is comparatively limited versus newer entrants; activity is typically maintenance and real-world oriented.
• Market outlook is flat to declining in the near term, shaped more by payer access and persistence than by incremental clinical differentiation.
• The most likely revenue trajectory depends on formulary status and patient retention, with upside tied to selective access wins and supply reliability.

---

FAQs

1. Is Bydureon used as a first-line GLP-1 in most formularies?
   Often not, because many plans prefer higher-momentum agents and use step therapy.

2. What drives Bydureon revenue more: new patients or persistence?
   Persistence among stable patients is typically the dominant driver for legacy injectable GLP-1 ER products.

3. Do GLP-1 outcomes narratives materially help Bydureon share?
   They help the category leaders most; Bydureon’s share gains are usually constrained by payer preference consolidation.

4. What clinical endpoints matter most for ongoing Bydureon use?
   Glycemic control, tolerability, and adherence-related outcomes in routine care.

5. What is the main commercial risk for Bydureon over the next few years?
   Accelerated switching to preferred semaglutide/tirzepatide products following formulary tightening.

---

References

[1] U.S. Food and Drug Administration (FDA). Bydureon (exenatide extended-release) prescribing information.
[2] FDA. Drug Safety and labeling information for exenatide extended-release.
[3] EMA. Public assessment and product information for exenatide (extended-release formulations).
[4] ClinicalTrials.gov. Clinical studies for exenatide extended-release (Bydureon).
[5] IQVIA / industry market outlook reports on GLP-1 and diabetes injectables (class-level dynamics and formulary shifts).